In:
Acta Radiologica, SAGE Publications
Abstract:
Advances in molecular imaging strategies have had an effect on precise diagnosis and treatment. Research has been intensified to develop more effective and versatile radiopharmaceuticals to uplift diagnostic efficiency and, consequently, the treatment. Purpose To label the flutamide (FLUT) coupled with diethylenetriamine pentaacetate (DTPA) with technetium-99 m ( 99m Tc) and to evaluate its binding efficiency with rhabdomyosarcoma (RMS) cancer cells. Material and methods Radiolabeling of FLUT with 185 MBq freshly eluted 99m TcO 4 −1 was carried out via DTPA bifunctional chelating agent using stannous chloride reducing agent at pH 5. The labeled compound was assessed for its purity using chromatography analysis, stability in saline and blood serum, AND charge using paper electrophoresis. Normal biodistribution was studied using a mouse model, while binding affinity with RMS cancer cells was studied using an internalization assay. The in vivo accumulation of RMS cancer cells in a rabbit model was monitored using a SPECT gamma camera. Results Radiolabeling reaction displayed a pharmaceutical yield of 97% and a stability assay showed 〉 95% intact radiopharmaceutical up to 6 h in saline and blood serum. In vitro internalization studies showed the potential of [ 99m Tc]DTPA-FLUT to enter into cancer cells. This biodistribution study showed rapid blood clearance and minimum uptake by body organs, and scintigraphy displayed the [ 99m Tc]DTPA-FLUT uptake by lesion, induced by RMS cancer cell lines in rabbit. Conclusion Stable, newly developed [ 99m Tc]DTPA-FLUT seeks its way to internalize into RMS cancer cells, indicating it could be a potential candidate for the diagnosis of RMS cancer.
Type of Medium:
Online Resource
ISSN:
0284-1851
,
1600-0455
DOI:
10.1177/02841851241249161
Language:
English
Publisher:
SAGE Publications
Publication Date:
2024
detail.hit.zdb_id:
2024579-8
Permalink
